Immunome, Inc. (IMNM) Stock Price & How to Invest

Immunome, Inc. is a Nasdaq-listed, clinical-stage targeted-oncology company developing cancer therapies. Its lead asset is varegacestat, a once-daily oral gamma secretase inhibitor for adults with progressing desmoid tumors; the company submitted a New Drug Application to the U.S. FDA in April 2026, backed by the Phase 3 RINGSIDE trial that showed an ~84% reduction in the risk of disease progression or death and a ~56% confirmed objective response rate versus ~9% for placebo. Behind that lead program sits an antibody-drug-conjugate (ADC) and radiotherapy pipeline, including IM-1021 (a ROR1 ADC), IM-3050 (a FAP-targeted radiotherapy), IM-1617, and additional preclinical candidates.

As a pre-commercial developer, Immunome generates only minimal collaboration-related revenue (roughly $7 million in 2025) against large research spending and recurring net losses, so the investment picture is not about earnings today. It is about whether varegacestat wins approval and launches successfully into a market where a rival oral therapy already exists, and whether the broader ADC engine produces additional clinical wins. A cash position of roughly $582.7 million as of March 2026 funds that plan into 2028, but the equity remains a speculative, catalyst-driven biotech.

As a clinical-stage biotech, Immunome is exposed to substantial binary risk: the FDA could delay, restrict, or reject varegacestat, and any label or safety concern would materially reset the stock. The company has minimal product revenue and posts recurring net losses (a net loss of roughly $53.8 million in Q1 2026), so it depends on its cash balance and, potentially, future capital raises that could dilute shareholders. Even with approval, commercial uptake is uncertain because an established oral competitor already serves the desmoid market. Pipeline candidates are early and most drug programs fail in development. The shares are volatile and can move sharply on single trial, regulatory, or insider-selling headlines.

13 analysts publish price targets on IMNM, averaging $35.77 against a $22.76 price as of August 2026, or +57.2%. The published targets run from $30.00 to $40.00, a narrow spread, and the ratings split 13 buy, 0 hold, 0 sell. Over the last six months there have been 2 raises and 2 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full IMNM forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Immunome, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Varegacestat FDA decision and launch. The submitted NDA for varegacestat in desmoid tumors is the single largest near-term driver. The most optimistic published target, $40.00, assumes this works close to its best case.

The case against. As a clinical-stage biotech, Immunome is exposed to substantial binary risk: the FDA could delay, restrict, or reject varegacestat, and any label or safety concern would materially reset the stock. The most pessimistic target, $30.00, is roughly what IMNM is worth if this bites instead.

Read the full bull and bear case on IMNM, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Immunome, Inc.'s investor relations page or your broker.

• Market cap: ~$2.6B
• Share price: ~$23
• Revenue (FY2025): ~$7M
• Cash & equivalents (Mar 2026): ~$582.7M
• Net loss (Q1 2026): ~$53.8M
• R&D expense (Q1 2026): ~$46.4M

Immunome trades on pipeline expectations, not profits, so conventional earnings multiples do not apply to a pre-commercial developer with minimal revenue and ongoing losses. Its roughly $2.6 billion market value largely reflects the market's probability-weighted view of varegacestat approval plus the ADC pipeline. The sizable cash balance funds operations into 2028 but does not by itself justify the valuation.

Other names that sit close to IMNM: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get IMNM exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so IMNM sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where IMNM fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

IMNM is a well-funded, pre-commercial cancer-drug developer whose value rides on varegacestat clearing the FDA and its ADC pipeline maturing, which makes it high-risk and event-driven rather than a cash-flow story.

Whether IMNM is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is IMNM a buy or a sell?, and where the stock could go from here in the IMNM stock forecast.

For income investors, whether IMNM pays a dividend and how the payout looks is covered in does IMNM pay a dividend? And to weigh IMNM against a peer, read the full side-by-side comparisons: IMNM vs ADC and IMNM vs AZN.